Travis Steed, an analyst from Bank of America Securities, reiterated the Buy rating on Medtronic. The associated price target remains the same with $100.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Travis Steed has given his Buy rating due to a combination of factors that suggest a positive outlook for Medtronic. Despite a slightly lower-than-expected revenue growth in the first quarter, the announcement of Elliott Management’s investment in Medtronic is seen as a favorable development. This investment, combined with the appointment of new independent directors, is expected to drive strategic changes and potentially accelerate Medtronic’s ongoing turnaround efforts.
Medtronic’s challenges in certain business areas, such as neurovascular and pelvic health, are anticipated to improve in the coming years. The company is addressing these issues with new product launches and organizational changes, which are expected to enhance performance. Furthermore, the alignment between Medtronic and Elliott Management is viewed as a positive step towards achieving long-term growth, supported by Elliott’s successful track record in the healthcare sector.
In another report released today, Barclays also reiterated a Buy rating on the stock with a $109.00 price target.